Compare Funko Inc (FNKO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Novo Nordisk A/S — how do they compare? Funko Inc trades at $6.23 (market cap $332.33M), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 625.4× Funko Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| FNKO | NVO | |
|---|---|---|
Market Cap | $332.33M | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $6.35 | $63.98 |
52-Week Low | $2.65 | $35.29 |
Enterprise Value | $552.98M | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.92, down 4.36% today, but maintains a bullish technical outlook with strong moving average signals. The company reported improved Q2 2026 results with 7% revenue growth to $207.7M and raised EBITDA guidance. Despite negative net margins, recent earnings beats and a low P/S ratio of 0.35 suggest undervaluation. Analyst sentiment is mixed with 43% buy ratings but no sell recommendations.
The outlook remains cautiously optimistic as Funko's turnaround strategy shows traction, though profitability challenges and negative cash flow from operations pose risks. The stock offers potential upside if management can sustain recent operational improvements and return to consistent profitability.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
